World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 4
Page: 538-548

ANTI-INFLAMMATORY DRUGS IN CHRONIC DISEASE MANAGEMENT: A COMPREHENSIVE REVIEW

Subhrajeet Dash[1*], Khipti Gayatri Mallick[2], Sonali Behera[3], Subhasmita Das[4], Monoranjan Sahu[5] and Swadhin Dash[6]

[1*]PhD Research Scholar, Driems University, Tangi, Cuttack, Odisha- 754022.
[2]Assistant Professor, Gayatri Institute of Science and Technology, Gyan Vihar, at-Regeda, Post-Gunupur, Dist-Rayagada, Odisha.
[3]Assistant Professor, Department of Pharmacology, Dr. Ambedkar Institute of Pharmaceutical Science, Rourkela- 769042.
[4]Assistant Professor, Department of Pharmacology, Dadhichi College of Pharmacy, Vidhya- Vihar, Sundargram, Cuttack- 754002.
[5]M.Pharm, Department of Pharmaceutics, Kanak Manjari Institute of Pharmaceutical Sciences, Rourkela, Odisha, 769015.
[6]Lecturer, Department of Pharmacology, Aurosri Institute of Pharmaceutical Education and Research, Cuttack, 754022.

Article Received: 05 July 2025 | | Article Revised: 26 July 2025 | | Article Accepted: 19 August 2025

***Corresponding Author: Subhrajeet Dash**
PhD Research Scholar, Driems University, Tangi, Cuttack, Odisha- 754022.
DOI: https://doi.org/10.5281/zenodo.16948600

How to cite this Article: Subhrajeet Dash, Khipti Gayatri Mallick, Sonali Behera, Subhasmita Das, Monoranjan Sahu and Swadhin Dash (2025). ANTI-INFLAMMATORY DRUGS IN CHRONIC DISEASE MANAGEMENT: A COMPREHENSIVE REVIEW. World Journal of Pharmaceutical Science and Research, 4(4), 538-548. https://doi.org/10.5281/zenodo.16948600

ABSTRACT

Chronic diseases are the leading cause of global morbidity and mortality, and chronic inflammation is a major underlying driver of their initiation, progression, and complications. Persistent inflammatory processes contribute to tissue damage and worsen conditions such as cardiovascular disease, diabetes, autoimmune disorders, neurodegenerative diseases, and chronic respiratory illnesses. Anti-inflammatory drugs form a cornerstone of chronic disease management by targeting key molecular and cellular pathways to reduce inflammation and limit disease progression. This review examines the pathophysiology of chronic inflammation, highlights major chronic diseases associated with it, and compares the mechanisms, efficacy, and safety of different classes of anti-inflammatory drugs, including NSAIDs, corticosteroids, conventional and biologic DMARDs, JAK inhibitors, and emerging novel agents. Clinical trial data, safety considerations, and cost-effectiveness are evaluated alongside non-pharmacological interventions such as diet, physical activity, and stress management. The role of precision medicine, biomarker-guided therapy, and innovative drug delivery systems is discussed as a pathway to more personalized and effective treatment strategies. Understanding the comparative benefits and limitations of anti-inflammatory therapies is essential to optimizing long-term disease control, minimizing adverse effects, and improving patient quality of life.

KEYWORDS: Chronic inflammation; Anti-inflammatory drugs; Chronic disease management; Disease-modifying anti-rheumatic drugs and Precision medicine.

INTRODUCTION

At a global level, chronic diseases represent the greatest health burden. Chronic diseases are the leading causes of death and illness around the world. Chronic diseases are also linked to chronic inflammation. Inflammation drives multiple disease processes and plays a role in disease initiation, progression and tissue damage. Effective management is required to curtail disease processes like inflammation. Anti-inflammatory drugs play a major role in chronic disease management to contain inflammation and progress of the disease. The purpose of this paper is to discuss the role of inflammation in chronic disease, comparison of effectiveness and assessment of outcome of various classes of anti-inflammatory drugs, chronic disease management beyond pharmacotherapy and continuous improvement and evolution of anti-inflammatory therapy in chronic disease.

Pathophysiology of Chronic Inflammation

Acute inflammation is a short-term response of the immune system, characterized by the fast recruitment of immune cells and the release of pro-inflammatory mediators, such as prostaglandins, with the function of eliminating the pathogen and beginning the process of tissue repair (Oyesola & Tait Wojno, 2021). Chronic inflammation, on the other hand, is an prolonged process that is maintained in time. It can be caused by continued exposure to irritants in low-grade intensity or due to dysregulation of cytokines and other mediators that cause persistent injury to tissues and disease progression (Wautier & Wautier, 2023). Acute inflammation has protective function while chronic inflammation can be maladaptive. In this sense, chronic inflammation is considered a key player in the development of cardiovascular diseases, as well as in autoimmune diseases. Hence, it may have distinctive functions and roles involving the participation of mediators at the cellular and molecular level that promote the development of specific pathologies. Thus the relevance of understanding the differences and particularities of acute and chronic inflammation processes in order to develop therapeutic strategies that selectively interfere with the consequences of chronic inflammation without compromising the consequences of acute inflammatory processes.

Along with this, some cellular and molecular mediators (such as cytokines and prostaglandins) greatly participate in chronic inflammation, affecting the course of chronic diseases and their pathology. Cytokines (such as interleukins and tumor necrosis factors) can be pro-inflammatory and anti-inflammatory mediators as well and can interact within networks either causing inflammation or inhibiting it (Wautier & Wautier, 2023). Cytokines directly affect both the initiation and development of inflammation, indicating their significance in maintaining inappropriate chronic inflammatory processes as well as resolving acute inflammation. Prostaglandins (PGE2, PGD2, PGI2, and others) affect the inflammatory process by increasing vascular permeability and recruiting immune cells; however, they also regulate the resolution of inflammation and restoring homeostasis processes (Schmid & Brüne, 2021). It is important to take into account the main mediators function in inflammation-related chronic diseases development for creating and implementing specific medical therapies aimed to control the inflammation process, preventing its further development and providing needed immune protection at the same time.

Furthermore, dysregulation of the immune system plays a significant role in chronic diseases as it promotes the inflammation to remain - in fact, there are several mechanisms contributing to immune system dysregulation inclusive of immune cells being activated inappropriately along with cytokines continue being secreted in a proinflammatory manner. Immune cells such as macrophages and T-cells can become dysfunctional, and the imbalance of immune systems regulatory pathways can lead to chronic inflammatory diseases (Furman et al., 2019). Inappropriate dysregulation of immune responds too chronic diseases can be stimulated through environmental and lifestyle factors

such as diet and stress. Therefore, a more detailed focus providing underlying knowledge related to immune dysregulation observed in chronic diseases will help to identify new targets which will allow the novel therapies to interrupt the chain reaction along with helping to decrease chronic inflammation to persist.

In consequence, chronic inflammation plays a major role in tissue injury and hasten disease development in various chronic diseases. Chronic inflammatory response leads to tissue injury through continuous overactive of immune cells that produces excess pro-inflammatory mediators and reactive oxygen species (ROS) that damages cellular structures and functions. Tissue injury results in many diseases such as cardiovascular diseases (CVD); vascular injury promotes arteriosclerosis that leads to heart attacks (Libby et al., 2024). Besides cardiovascular diseases, inflammation worsens neuronal injury in neurodegenerative diseases such as Alzheimer's disease through promoting formation of amyloid plaques and tau-tangles, resulting in cognitive decline. Thus, understanding how inflammation causes and worsens tissue injury is valuable in understanding its role in chronic inflammatory diseases, and the knowledge can emphasize the demands of potent therapeutics to interrupt the process while upholding normal physiological functions.

Chronic Diseases Linked to Persistent Inflammation

Chronic inflammation has a significant role in the development of CVDs. There are specific inflammatory pathways which are critically involved in its manifestation. Studies reported that pathogenic activation of the innate immune system and specifically the NLRP3 inflammasome pathway contributes in aggravating atherosclerosis and associated CVDs (Mezzaroma et al., 2021). NLRP3 inflammasome signaling is a major core platform for triggering inflammatory cascade on sterile injuries which causes atherothrombotic events. IL-1β pathway inhibition using canakinumab showed promising reduction in occurrences of cardiovascular events as demonstrated in CANTOS trial (Satish & Agrawal, 2020). This indicates that inflammatory pathways can be targeted for improving therapeutic approaches against CVDs to counter atherosclerosis and associated morbidities.

Likewise, chronic inflammation is also another contributor to the development of diabetes. It enhances the pathogenesis of the disease through multiple processes. The antigens that drive the development of immune response in type 1 diabetes and the inflammatory mediators such as TNF-α and interleukins lead to insulin resistance (Furman et al., 2019). It mediates the process of insulin signaling pathway, beta-cell dysfunction and apoptosis, leading to hyperglycemia in type 1 and type 2 diabetes. On the other hand, epigenetic alterations to the environment and lifestyle, obesity, and sedentary lifestyle lead to enhanced inflammatory response which continues to promote epigenetic changes and inflammatory mediators, leading to imbalance in metabolism and development of chronic inflammation (Ramos-Lopez et al., 2021). Hence understanding the causal link of all such sites could help understand the pathogenesis of inflammation-associated pathways and develop a holistic approach to deal with inflammation as the core factor developing diabetes mellitus, which is why it is such an important aspect to deal with along anti-inflammatory drugs in control of blood glucose.

In addition to that RA and CKD are similar in terms of the common inflammatory pathways that directed their disease progression and mechanism. In RA, chronic inflammation leads to hyperplasia of the synovial and damage to the joints with the involvement of pro-inflammatory cytokines such as TNF-α and interleukins. The synovial cells and immune cells are activated resulting in the continuation of the inflammatory process (Furman et al., 2019). During CKD, chronic inflammation is observed with increased levels of cytokines which could lead to renal fibrosis and affect renal functioning. These pathways are similar in RA and CKD and provide an insight on how inflammation correlated them

together. The involvement of inflammatory factors led to the development of chronic inflammation with immune cell infiltration and oxidative stress aggravating the damage done to the target tissue (Libby et al., 2024). These evidence would help understand the correlation among conditions, thereby providing an expected outcome in further therapeutic pathways targeting these common processes. These could be beneficial in reducing chronic inflammation and provide a protective measure against disease development with similar pathogenic features.

Also, neurodegenerative diseases and chronic respiratory illnesses are significantly attributing the inflammatory processes to determine their pathogenesis. Inflammation in neurodegenerative disease, such as Alzheimer's and Parkinson diseases are intrinsically involve activated microglia and astrocyte, which releases several pro-inflammatory cytokines, which inflict neuronal injury (Blevins et al., 2022). These inflammatory mediators recruitment leads to protein aggregates build-up, resulting in neurodegeneration and cognitive as well as motor function loss. Similarly, chronic respiratory diseases, such as chronic obstructive pulmonary diseases (COPD) and asthma are significantly driven by inflammation, causing airway obstruction and remodeling. Persistent inflammatory infiltrate with neutrophils and eosinophils cause lung tissue damage and respiratory dysfunction, leading to symptom exacerbation and disease progression (Libby et al., 2024). Investigating the role of inflammation in these diseases could help in developing anti-inflammatory targeted medications that could potentially halt or reverse mechanisms established by inflammation in these diseases.

Classes of Anti-inflammatory Drugs

Various classes of anti-inflammatory drugs are used for controlling chronic inflammation characterized by various mechanisms and ranges of indications. One of the classes is known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that blocks cyclooxygenase (COX) and prevents the synthesis of prostaglandins that have pro-inflammatory effects, therefore alleviating pain and controlling inflammation (Wirth et al., 2024). However, NSAIDs have risks that should be weighed before being prescribed particularly associated with unfavorable cardiovascular outcomes and renal toxicity in susceptible individuals, especially known chronic kidney disease (CKD) patients. Other example of the key classes is corticosteroids that prevent inflammation by inhibiting immune reactions and mainly indicated for diseases that require strong anti-inflammatory actions, but could lead serious side effects in the forms of glucocorticoid-induced disease, such as osteoporosis and immunosuppression (Wirth et al., 2024). Nevertheless, acknowledging the indications and boundaries of each class would allow for the best therapeutic options available for controlling inflammation as a part of management strategy in chronic diseases with fitted effects and minimum adverse outcomes.

Table 1: Comparison of Major Classes of Anti-Inflammatory Drugs.

Drug Class	Mechanism of Action	Common Uses	Key Side Effects	Examples
NSAIDs	Inhibit COX-1 and COX-2 → block prostaglandin synthesis	Arthritis, musculoskeletal pain, CVDs	GI ulcers, renal toxicity, CV risk	Ibuprofen, Naproxen, Diclofenac
Corticosteroids	Inhibit phospholipase A2, suppress pro-inflammatory gene expression	Autoimmune diseases, asthma, IBD	Immunosuppression, osteoporosis, hyperglycemia	Prednisone, Dexamethasone
csDMARDs	Suppress immune cell proliferation and cytokine activity	Rheumatoid arthritis, lupus	Hepatotoxicity, bone marrow suppression	Methotrexate, Sulfasalazine
bDMARDs	Target specific cytokines (e.g., TNF-α, IL-6)	Autoimmune diseases	Infection risk, injection site reactions	Infliximab, Tocilizumab
JAK Inhibitors	Block JAK-STAT signaling pathways in immune cells	Psoriasis, RA, ulcerative colitis	Thrombosis, lipid elevation	Tofacitinib, Baricitinib

NSAIDs

The main pharmacological action of Non-Steroidal Anti-Inflammatory Drugs is attributed to the inhibition of cyclooxygenase in the synthesis of prostaglandins to excrete inflammatory place and pain signs. The therapeutic effect of NSAIDs is primarily analgesic and anti-inflammatory and is widely used in practice for effective deference in arthritis and chronic diseases of the musculoskeletal system (Wirth et al., 2024). The diversity of NSAIDs is limited due to certain side effects such as potential increased cardiovascular risk and nephrotoxicity. Such side effects provide a comparative selection of NSAIDs based on individual patient characteristics (Ribeiro et al., 2022). Non-selective NSAIDs also include ibuprofen and naproxen, the dosing regimen for which should be adjusted according to normative pharmacokinetic and pharmacodynamic parameters in patients over 65 years of age (Ribeiro et al., 2022). Understanding the advantages and disadvantages of NSAIDs dictates the need for prescribing them with mandatory consideration of all adverse events, the implementation of which will allow avoiding complications and exerting the maximum therapeutic effect in treatment chronic inflammation.

Corticosteroids

Chronic inflammation responds well to corticosteroids as they are highly anti-inflammatory drugs that suppress diverse elements of immune response and repress the expression of pro-inflammatory genes (Libby et al., 2024). Corticosteroids have best indications in rheumatoid arthritis and inflammatory bowel diseases, exacerbated asthma and other diseases where a strong anti-inflammatory effect is required to ameliorate the disease progress and to give positive treatment outcome. However, corticosteroids are associated with numerous adverse effects that also hugely impact the long-term treatment options, including but not limited to osteoporosis, hyperglycemia, infection susceptibility (Libby et al., 2024). The long-term use of corticosteroids demands extra care to avoid side effects but at the same time, disease population is seen progressing due to uncontrolled inflammation. The chronic effect of corticosteroids demonstrates the importance of reducing inflammation and saving the underlying disease progress and its outcomes to make sure its Disease-Modifying Anti-Rheumatic Drugs (DMARDs) constitute the mainstay of core treatment for chronic inflammatory diseases and are further divided in conventional synthetic (csDMARDs) and biologic DMARDs (bDMARDs). The conventional DMARDs methotrexate and sulfasalazine predominantly act on the proliferation and activity of immune cells, affecting the level of pro-inflammatory cytokines and thus alleviating disease activity and preventing joint damage in rheumatoid arthritis (Blevins et al., 2022). Whereas biologic DMARDs, comprised of monoclonal antibodies and receptor fusion proteins, neutralize cytokines or specific cell surface molecules and thus specifically modulate immune processes without general immunosuppression. Examples are TNF inhibitors and interleukin-6 blockers targeting specific pathways involved in signal transduction. DMARDs, both csDMARDs and bDMARDs acquire distinct limitations due to their immunosuppressive characteristics, influencing the specific susceptibility of patients to infections.

DMARDs

JAK and PDE4 inhibitors, as targeted synthetic drugs, play crucial role in treating some chronic inflammatory disorders which rely on inflammatory cytokines. JAK inhibitors block the JAK proteins present in immune cells and ultimately block the signaling for many cytokines leading to enhanced inflammatory disease such as psoriasis and rheumatoid arthritis (Blevins et al., 2022). The role of PDE4 inhibitors such as apremilasat, works by blocking the cyclic AMP(cAMP) degradation, it decrease the inflammatory cytokines expression and upregulated anti-inflammatory cytokines. PBS4 inhibitors are increasingly used for psoriasis, psoriatic arthritis and atopic diseases (Blevins et al.,

2022). Therefore, delivering JAK and PDE4 inhibitors for treating chronic inflammatory disorders shows their role in controlling disorder, these inhibitors restrictedly work for specific target pathway rather than blocking whole immune mediators pathway, depicts their balanced approach to regain control for inflammatory disorder.

Immunomodulators and Targeted Synthetic Agents

New therapies being explored for chronic inflammatory diseases include new agents like monoclonal antibodies, NLRP3 inflammasome inhibitors and anti-inflammatories from plants or plant extracts. Monoclonal antibodies are becoming a new agents targeting specific cytokines like IL-6, TNF-α which expands the therapeutic horizon by blocking major pro-inflammation pathways and benefiting autoimmune diseases patients (Blevins et al., 2022). The new generations of NLRP3 inhibitors like ADS032 are showing potential to inhibit inflammation by targeting the pathways responsible for IL-1β release to target the link in the chain of inflammation (Docherty et al., 2023). ADS032 was shown in researches to decrease pulmonary inflammation in vivo making it a candidate to the treatment of inflammatory disorders driven by NLRP3 (Docherty et al., 2023). Using anti-inflammatories in plants that utilize the bioactive ingredients present in them to target immune system signals shows the diversification of new ideas targeting chronic inflammatory diseases to present effective and sustainable alternatives.

Novel Agents

The critical refinement of data to assess the relative effectiveness of specific anti-inflammatory medications in the management of chronic diseases is the analysis of the effectiveness data in clinical trials. NSAIDs are widely consumed for pain relief and anti-inflammatory effects. The risk of cardiovascular disease and heterogeneous nature of clinical trials poses difficulties in its safety assessment (Rane et al., 2019). As mention in comprehensive reviews and observational studies, large randomized trials with specific target goals are required to assess the relative effectiveness of the medications and its intricate balance of benefits, risks, and uncertainties associated with its use (Rane et al., 2019). In contrast, monoclonal antibodies, like canakinumab, showed promising ability to reduce atherothrombotic events targeting specific inflammatory pathways (IL-1β) revealed during chronic diseases progression (Mezzaroma et al., 2021). These results promote the usage of thoughtful specific therapies targeting effective and patient tailored specific pathways with promising safety to promote therapeutic success.

In addition, the comparison of cost-effectiveness of anti-inflammatory drugs should also include the analysis of their short-term and long-term economic effects. Although NSAIDs can be more readily used owing to lower costs, adverse effects of this class of drugs can contribute to increased healthcare costs in the long term and should be taken into consideration (Rane et al., 2019). Long-term complications such as gastrointestinal bleeding and cardiovascular diseases can contribute to additional healthcare costs thereby increasing healthcare burden. On the other hand, biologics such as monoclonal antibodies can have higher upfront costs, but may provide healthcare savings by effectively limiting disease progression and reducing rates of hospitalizations attributable to inflammatory chronic diseases. Hence, the cost-effectiveness evaluation of the aforementioned anti-inflammatory drugs should take into consideration both their short-term costs and benefits and their long-term financial implications based on their ability to reduce the rates of complications and healthcare burden. Overall, the cost-effectiveness evaluation should adopt a comprehensive approach in analyzing the financial implications of the drugs at hand in order to avoid inefficient allocation of healthcare resources in the management of the chronic disease.

Evaluating the comparative effectiveness of various anti-inflammatory drugs in chronic disease management requires a thorough analysis of efficacy data from clinical trials. NSAIDs, despite widespread use for their analgesic and anti-inflammatory properties, present challenges due to concerns about their cardiovascular risks and inconsistent trial methodologies, as highlighted in detailed reviews and observational studies (Rane et al., 2019). The need for large-scale randomized trials with targeted objectives is emphasized to better understand the nuanced benefits and potential harms of these drugs (Rane et al., 2019). On the other hand, monoclonal antibodies such as canakinumab have demonstrated substantial efficacy in reducing atherothrombotic events by specifically inhibiting components of inflammatory pathways like IL-1β (Mezzaroma et al., 2021). These findings underline the importance of carefully tailored therapies that not only target disease-specific pathways effectively but also consider patient-specific safety profiles to enhance therapeutic outcomes in chronic disease management.

Turning now to the analysis of the negative impact of anti-inflammatory agents, extremely pronounced gastrointestinal and renal disorders occur in patients after admission of nonsteroidal anti-inflammatory drugs (NSAIDs). The main etiological factor of these complications is a significant violation of the activity of cyclooxygenase (COX) enzymes, leading to inhibition of the formation of a protective glycocalyx and inflammation of the gastric mucosa (Rane et al., 2019). The destructive influence on the kidneys is caused by the ability of NSAIDs to reduce the volume of blood entering the kidneys and the development of acute renal failure in patients with pre-existing renal disorders (Ribeiro et al., 2022). An effective way to reduce the probability of side effects is the selection of NSAIDs with a low level of renal excretion and a pronounced sign of appeared in phase 2 metabolism. Selective COX-2 inhibitors are selective in nature and have the lowest level of gastrointestinal side effects with low impact on kidney function, especially with great efficiency for the elderly and polymedicated patients (Ribeiro et al., 2022). Effective prescribing strategies for reducing gastrointestinal complications in patients lie in the co-prescription of proton pump inhibitors or the strict adherence to a short course of therapy at low doses. All possible methods emphasize the relevance of a personalized and individualized approach to the therapeutic process and decision making.

Furthermore, the potential cardiovascular safety concerns need to be evaluated in-depth when prescribing long-term anti-inflammatory drugs considering their significant impact. Non-steroidal anti-inflammatory drugs (NSAIDs) particularly the selective cyclooxygenase-2 inhibitors (COXIBs) have been proved to increase cardiovascular risk that resulted in cardiovascular events including myocardial infarction and hypertension (Rane et al., 2019) . The challenges in understanding these cardiovascular risks further aggravated due to the limitations in trial methodologies such as absence of hypothesis in pre-defined trials and the bias in observational studies (Rane et al., 2019) . Cardiovascular risks could be minimized through utilizing approach strategies such as dose reduction, intermittent dosing schedule, and utilization of alternative drugs like low-dose aspirins for cardiovascular protection especially in patients with high cardiovascular risk. Most importantly, cardiovascular risk and safety could be improved through personalized treatment approach based on risk evaluation, the monitoring of cardiovascular profile in patients for extended use of anti-inflammatory drugs in long-term management of chronic diseases.

Examining the adverse effects of anti-inflammatory drugs reveals significant gastrointestinal and renal concerns, particularly with nonsteroidal anti-inflammatory drugs (NSAIDs). Gastrointestinal complications, such as ulcers and bleeding, are primarily caused by the inhibition of cyclooxygenase (COX) enzymes, which decrease the protective lining of the stomach (Rane et al., 2019). Renal adverse effects arise because NSAIDs can reduce renal blood flow,

potentially causing acute kidney injury, especially in patients with pre-existing kidney conditions (Ribeiro et al., 2022). To mitigate these risks, prescribing NSAIDs with lower renal excretion and phase 2 metabolism, such as selective COX-2 inhibitors, may be safer options as these have fewer gastrointestinal side effects and are more kidney-friendly, particularly for elderly and polymedicated patients (Ribeiro et al., 2022). Additionally, implementing strategies such as the co-prescription of proton pump inhibitors or adhering to short-term, low-dose regimens can further reduce gastrointestinal risks, underscoring the importance of tailored therapeutic approaches.

Diet and physical activity are two important non-pharmacological interventions to reduce inflammation in patients with chronic diseases. The dietary pattern has a strong effect on inflammation through different mechanisms. One of the mechanisms is the alteration of gut microbiota. Gut microbiota plays a dominant role in immune system function and metabolism of phytochemicals and nutrients (Margină et al., 2020). A diet containing high dietary fiber and nutrients helps to produce short-chain fatty acids which strengthens the intestinal barrier and decreases systemic inflammation. Regular physical activity also promotes healthy inflammatory profile by modulating systemic signalling and mechanisms like fatty acid mobilisation in skeletal muscles (Burini et al., 2020). Lifestyle recommendations including balanced diet and physical activity should be emphasized to patients with chronic diseases to reduce chronic inflammation. This is because lifestyle modifications can boost immune function and promote health and disease prevention.

In addition to this, stress management and microbiome modulation could be significant non-pharmacological therapies to manage chronic inflammation. It is important to note that psychological stress had activated inflammatory pathways resulting in augmenting the inflammatory background of chronic disease. Therefore, the application of stress management techniques as mindfulness and cognitive behavioral therapies promotes inflammatory pathways reduction (Margină et al., 2020). In addition to stress management, gut microbiome modulation could have a major role in restoring the inflammatory process. Gut microbiome modulates the immune system and induces inflammation through the secretion of bioactive metabolites as short-chain fatty acids, improving intestinal barrier functions and reducing systemic inflammation (Margină et al., 2020). The addition of these strategies to pharmacotherapy has the potential to improve the control of the inflammatory process, primarily through the implementation of lifestyle changes, endorsing another factor in the management of chronic diseases.

Diet and physical activity are fundamental non-pharmacological strategies for mitigating inflammation in chronic disease management. Diet significantly influences inflammation through various pathways, particularly by modulating the gut microbiota, which plays a crucial role in the immune response and metabolism of dietary components (Margină et al., 2020). Consuming a diet rich in dietary fiber and nutrients facilitates the production of short-chain fatty acids, which enhance intestinal barrier function and reduce systemic inflammation. Similarly, physical activity contributes to an improved inflammatory profile by regulating systemic signaling and employing mechanisms such as the utilization of fatty acids in skeletal muscles (Burini et al., 2020). Therefore, recommending lifestyle changes, including a balanced diet and regular physical activity, is vital for managing chronic inflammation, as these strategies not only enhance immune function but also support overall health and disease prevention.

The evolution of precision medicine holds promising opportunities for improving the effectiveness of anti-inflammatory agents in chronic disease treatment. Precision medicine is based on AI and large datasets, adapting therapeutic strategies to the unique profiles of patients (Subramanian et al., 2020). AI-assisted precision medicine

incorporates genetic, epigenetic, microbiome data and develops algorithms to identify specific biomarkers that can predict the response of a particular patient to certain anti-inflammatory drugs (Subramanian et al., 2020). Such a personalized approach will improve risk estimation and allow timely interventions. Consequently, patient management could be enhanced by better alignment with various biological and lifestyle factors. The evolution and implementation of biomarker-guided therapy in medical practice indicate a breakthrough in chronic disease management, promising the potential for more precise and effective chronic inflammation containment.

Moreover, advances in drug delivery systems and combination therapies are emerging as promising results towards improving existing tools available against chronic diseases. Innovative delivery platforms like nanoparticles and liposomes ensure site-specific targeting and controlled release of antiinflammatory medications, thus achieving better efficacy and lesser systemic toxicity. These systems provide better control on drug concentrations at site of inflammation whilst ensuring better adherence and treatment results. In addition, the co-administration of multiple therapeutic agents, including traditional antiinflammatory medications with novel classes of medications such as monoclonal antibodies or immunomodulators can provide a synergistic boost in their efficacy against chronic inflammatory pathways. These integrated approaches also match with individualization policies together with the benefits provided by precision medicine and artificial intelligence making chronic diseases more manageable and resilient today (Subramanian et al., 2020).

Advancing precision medicine provides promising possibilities for enhancing the efficacy of anti-inflammatory drugs in chronic disease management. By integrating artificial intelligence (AI) and utilizing large datasets, precision medicine offers a tailored approach, optimizing therapeutic interventions to individual patient profiles (Subramanian et al., 2020). Leveraging genetic, epigenetic, and microbiome data, AI-powered precision medicine enables the identification of specific biomarkers that predict patient responses to various anti-inflammatory treatments (Subramanian et al., 2020). This personalized strategy facilitates early interventions and more accurate risk assessments, potentially improving clinical outcomes by aligning treatments with individual biological and lifestyle factors. Overall, the development and implementation of biomarker-guided treatments signify a transformative advancement in chronic disease management, potentially leading to more nuanced and effective control of chronic inflammation.

Studying chronic disease treatment with anti-inflammatory drugs can help conceptualize the importance of individualized treatment approaches. Due to the intricate links between inflammation and chronic diseases, higher therapeutic efficacy may be achieved through a treatment approach considering individual patient characteristics. Customized treatment approaches may also help reduce the risks from long-term use of anti-inflammatory drugs and meet individualized patient requirements, alongside current advances in precision medicine. Besides, drug innovation, including new medicines and advanced delivery systems, continues to grow, providing additional options for clinicians treating chronic inflammation. As researchers gain a better understanding of inflammatory pathways, these drugs may play a more significant role in limiting the progression of chronic disease and improving the patient’s quality of life.

Table 2: Comparative efficacy, onset of action, risk profile, long-term suitability, and cost considerations of major classes of anti-inflammatory drugs used in chronic disease management.

Drug Type	Efficacy in Inflammation Control	Onset of Action	Risk of Adverse Events	Long-Term Use Suitability	Cost Level
NSAIDs	Moderate	Fast	High (GI, renal, CV)	Not suitable for long-term	Low
Corticosteroids	High	Fast	High (metabolic, bone)	Not preferred	Moderate
csDMARDs	High	Slow (weeks)	Moderate	Suitable with monitoring	Low
bDMARDs	Very High	Moderate	Moderate to high	Suitable with caution	High
JAK Inhibitors	High	Moderate	Moderate (vascular)	Suitable with caution	High

CONCLUSION

The exploration of anti-inflammatory drugs within the context of chronic disease management underscores the critical need for personalized treatment strategies. Given the complex interactions between inflammation and chronic diseases, a nuanced approach that considers individual patient profiles can significantly enhance therapeutic outcomes. Tailored treatment plans not only provide the potential to mitigate the adverse effects associated with prolonged anti-inflammatory drug use but also align with advancements in precision medicine to address patient-specific needs. Furthermore, the continual evolution of drug development, including novel agents and advanced delivery systems, highlights an expanding toolkit for clinicians managing chronic inflammation. As the understanding of inflammatory pathways deepens, these compounds are poised to play an increasingly integral role in curbing disease progression and improving the quality of life for affected individuals.

REFERENCES

1. Blevins, H. M., Xu, Y., Biby, S., & Zhang, S., The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. *Frontiers in Aging Neuroscience*, 2022; *14*. https://doi.org/10.3389/fnagi.2022.879021
2. Burini, R. C., Anderson, E., Durstine, J. L., & Carson, J. A., Inflammation, physical activity, and chronic disease: An evolutionary perspective. *Sports Medicine and Health Science*, 2020; *2*(1): 1–6. https://doi.org/10.1016/j.smhs.2020.03.004
3. Docherty, C. A., Fernando, A. J., Rosli, S., Lam, M., Dolle, R. E., Navia, M. A., Farquhar, R., La France, D., Tate, M. D., Murphy, C. K., Rossi, A. G., & Mansell, A., A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. *Clinical & Translational Immunology*, 2023; *12*(6): e1455. https://doi.org/10.1002/cti2.1455
4. Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., Franceschi, C., Ferrucci, L., Gilroy, D. W., Fasano, A., Miller, G. W., Miller, A. H., Mantovani, A., Weyand, C. M., Barzilai, N., Goronzy, J. J., Rando, T. A., Effros, R. B., Lucia, A., Kleinstreuer, N., & Slavich, G. M., Chronic inflammation in the etiology of disease across the life span. *Nature Medicine*, 2019; *25*: 1822–1832. https://doi.org/10.1038/s41591-019-0675-0
5. Libby, P., Smith, R., Rubin, E. J., Glassberg, M. K., Farkouh, M. E., & Rosenson, R. S., Inflammation unites diverse acute and chronic diseases. *European Journal of Clinical Investigation*, 2024; *54*(11): e14280. https://doi.org/10.1111/eci.14280
6. Margină, D., Ungurianu, A., Purdel, C., Tsoukalas, D., Sarandi, E., Thanasoula, M., Tekos, F., Mesnage, R., Kouretas, D., & Tsatsakis, A. Chronic inflammation in the context of everyday life: dietary changes as mitigating

factors. *International Journal of Environmental Research and Public Health*, 2020; *17*(11): 4135. https://doi.org/10.3390/ijerph17114135

7. Mezzaroma, E., Abbate, A., & Toldo, S., NLRP3 inflammasome inhibitors in cardiovascular diseases. *Mdpi.Com*, 2021; *26*(4): 976. https://doi.org/10.3390/molecules26040976
8. Oyesola, O. O., & Tait Wojno, E. D., Prostaglandin regulation of type 2 inflammation: From basic biology to therapeutic interventions. *European Journal of Immunology*, 2021; *51*(10): 2399–2416. https://doi.org/10.1002/eji.202048909
9. Ramos-Lopez, O., Milagro, F. I., Riezu-Boj, J. I., & Martinez, J. A., Epigenetic signatures underlying inflammation: An interplay of nutrition, physical activity, metabolic diseases, and environmental factors for personalized nutrition. *Inflammation Research*, 2021; *70*: 29–49. https://doi.org/10.1007/s00011-020-01425-y
10. Rane, M. A., Foster, J. G., Wood, S. K., Hebert, P. R., & Hennekens, C. H., Benefits and risks of nonsteroidal anti-inflammatory drugs: methodologic limitations lead to clinical uncertainties. *Therapeutic Innovation & Regulatory Science*, 2019; *53*(4): 502–505. https://doi.org/10.1177/2168479018794159
11. Ribeiro, H., Rodrigues, I., Napoleão, L., Lira, L., Marques, D., Veríssimo, M., Andrade, J. P., & Dourado, M., Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features. *Biomedicine & Pharmacotherapy*, 2022; 150: 112958. https://doi.org/https://doi.org/10.1016/j.biopha.2022.112958
12. Satish, M., & Agrawal, D. K., Atherothrombosis and the NLRP3 inflammasome–endogenous mechanisms of inhibition. *Translational Research*, 2020; *215*: 75–85. https://doi.org/10.1016/j.trsl.2019.08.003
13. Schmid, T., & Brüne, B., Prostanoids and resolution of inflammation–beyond the lipid-mediator class switch. *Frontiers in Immunology*, 2021; *12*. https://doi.org/10.3389/fimmu.2021.714042
14. Subramanian, M., Wojtusciszyn, A., Favre, L., Boughorbel, S., Shan, J., Letaief, K. B., Pitteloud, N., & Chouchane, L., Precision medicine in the era of artificial intelligence: implications in chronic disease management. *Journal of Translational Medicine*, 2020; *18*(472). https://doi.org/10.1186/s12967-020-02658-5
15. Wautier, J.-L., & Wautier, M.-P., Pro- and Anti-Inflammatory Prostaglandins and Cytokines in Humans: A Mini Review. *International Journal of Molecular Sciences*, 2023; *24*(11): 9647. https://doi.org/10.3390/ijms24119647
16. Wirth, T., Lafforgue, P., & Pham, T., NSAID: Current limits to prescription. *Joint Bone Spine*, 2024; *91*(4): 105685. https://doi.org/https://doi.org/10.1016/j.jbspin.2023.105685